P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)

• T. A. Eyre,
• N. N. Shah,
• S. Le Gouill,
• M. Dreyling,
• E. Vandenberghe,
• W. Jurczak,
• Y. Wang,
• C. Y. Cheah,
• M. Gandhi,
• C. Chay,
• J. P. Sharman,
• D. J. Andorsky,
• M. Yin,
• M. Balbas,
• J. Kherani,
• M. L. Wang

Affiliations

T. A. Eyre

1 Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom

N. N. Shah

2 Medical College of Wisconsin, Milwaukee, United States of America

S. Le Gouill

3 Service d’hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France

M. Dreyling

4 Medicine III, LMU University Hospital, Munich, Germany

E. Vandenberghe

5 Hope Directorate St. James Hospital, Dublin, Ireland

W. Jurczak

6 Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

Y. Wang

7 Division of Hematology, Mayo Clinic, Rochester, United States of America

C. Y. Cheah

8 Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia

M. Gandhi

9 Virginia Cancer Specialists, Fairfax

C. Chay

10 Messino Cancer Centers, Asheville

J. P. Sharman

11 Willamette Valley Cancer Institute and Research Center, US Oncology Research

D. J. Andorsky

12 Rocky Mountain Cancer Centers, US Oncology Research, Eugene

M. Yin

13 Loxo Oncology at Lilly, Stamford

M. Balbas

13 Loxo Oncology at Lilly, Stamford

J. Kherani

13 Loxo Oncology at Lilly, Stamford

M. L. Wang

14 University of Texas MD Anderson Cancer Center, Houston, United States of America